Literature DB >> 10745408

Intravenous pulse cyclophosphamide--a new regime for steroid resistant focal segmental glomerulosclerosis.

S Gulati1, V Kher.   

Abstract

OBJECTIVE: A prospective study was conducted to evaluate the role of intravenous pulse cyclophosphamide (IVCP) infusions in the management of children with steroid resistant (SR) idiopathic focal segmental glomerulosclerosis (FSGS).
METHODS: The study group comprised of 20 consecutive children with idiopathic nephrotic syndrome secondary to FSGS who were SR. All of them were subjected to standard baseline investigations. They were started on monthly infusions of IVCP in a dose of 500-750 mg/m2. Adjunctive prednisolone was given in a dose of 60 mg/m2/day for 4 weeks followed by 40 mg/m2/alternate day for another 4 weeks and tapered off over next 4 weeks.
RESULTS: The study group comprised of 15 boys and 5 girls with mean age of onset of disease of 5.5 +/- 3.5 years. Two of these children had chronic renal insufficiency prior to starting therapy. At the end of the study, after a mean duration of disease (since onset of NS) of 77 +/- 55 months, all 20 children had normal renal functions. After a mean follow up post IVCP therapy of 21.2 +/- 13.4 months, 13 of the 20 children (65%) had attained a complete remission. Of these, 10 children were infrequent relapsers, 2 frequent relapsers and 1 steroid dependent. The mean duration of remission following last dose of IVCP in these children was 12.5 +/- 11.9 months. Of the 7 children who continued to be proteinuric, 3 became edema free and have not required any albumin infusion or diuretics. One other died due to peritonitis 2 years after the last dose of IVCP. The mean total protein and serum albumin levels following the IVCP infusion were significantly higher than those prior to therapy (6.5+/-1.0 mg/dl Vs 5.0+/-0.8) (p=0.0004) and (3.5+/-0.7 g/dl Vs 2.3+/0.7) (p = 0.000007) respectively. The serum creatinine levels following IVCP therapy (0.8+/-0.2 mg/dl) were significantly lower than those prior to treatment (1.0+/-0.6 mg/dl) (p=0.02). The only side effects that were observed were transient nausea and vomiting during infusion (n=2) and alopecia (n=1). None of the children developed leukopenia or hemorrhagic cystitis.
CONCLUSION: IVCP infusions appear to be safe, effective and economical therapeutic modality in steroid resistant children with idiopathic FSGS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10745408

Source DB:  PubMed          Journal:  Indian Pediatr        ISSN: 0019-6061            Impact factor:   1.411


  12 in total

Review 1.  New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome.

Authors:  Michael van Husen; Markus J Kemper
Journal:  Pediatr Nephrol       Date:  2011-01-13       Impact factor: 3.714

2.  Intravenous cyclophosphamide in steroid-resistant nephrotic syndrome.

Authors:  Anurag Bajpai; Arvind Bagga; Pankaj Hari; Amit Dinda; Rajendra N Srivastava
Journal:  Pediatr Nephrol       Date:  2003-03-21       Impact factor: 3.714

3.  Efficacy of intravenous pulse cyclophosphamide treatment versus combination of intravenous dexamethasone and oral cyclophosphamide treatment in steroid-resistant nephrotic syndrome.

Authors:  Mukta Mantan; Chenni S Sriram; Pankaj Hari; Amit Dinda; Arvind Bagga
Journal:  Pediatr Nephrol       Date:  2008-06-20       Impact factor: 3.714

4.  Mesenteric thrombosis causing short bowel syndrome in nephrotic syndrome.

Authors:  Tim Ulinski; Vincent Guigonis; Valérie Baudet-Bonneville; Frédéric Auber; Karine Garcette; Albert Bensman
Journal:  Pediatr Nephrol       Date:  2003-10-15       Impact factor: 3.714

Review 5.  Corticosteroid-resistant nephrotic syndrome with focal and segmental glomerulosclerosis : an update of treatment options for children.

Authors:  Jochen H H Ehrich; Lars Pape; Mario Schiffer
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

6.  Clinical course and NPHS2 analysis in patients with late steroid-resistant nephrotic syndrome.

Authors:  Peter Schwaderer; Tanja Knüppel; Martin Konrad; Otto Mehls; Karl Schärer; Franz Schaefer; Stefanie Weber
Journal:  Pediatr Nephrol       Date:  2007-11-14       Impact factor: 3.714

Review 7.  Steroid resistant nephrotic syndrome.

Authors:  Sushmita Banerjee
Journal:  Indian J Pediatr       Date:  2002-12       Impact factor: 1.967

8.  Therapies for steroid-resistant nephrotic syndrome.

Authors:  Elisabeth M Hodson; Jonathan C Craig
Journal:  Pediatr Nephrol       Date:  2008-03-27       Impact factor: 3.714

9.  Intravenous pulse cyclophosphamide--is it effective in children with steroid-resistant nephrotic syndrome?

Authors:  Hammad O Alshaya; Jaudah A Al-Maghrabi; Jameela A Kari
Journal:  Pediatr Nephrol       Date:  2003-09-17       Impact factor: 3.714

Review 10.  Immunosuppressive treatment for focal segmental glomerulosclerosis in adults.

Authors:  Norbert Braun; Frank Schmutzler; Catalina Lange; Annalisa Perna; Giuseppe Remuzzi; Teut Risler; Narelle S Willis
Journal:  Cochrane Database Syst Rev       Date:  2008-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.